PTEN and neoplasm: Indeed, at 7–8 weeks of age, genetically engineered mouse models (GEMMs) with specific deletion of PTEN in prostate epithelial cells (Ptenpc−/− mice) developed premalignant prostatic lesions characterized by a strong senescence response that counteracted tumor progression.